Literature DB >> 10508193

Monogenic disorders of obesity and body fat distribution.

D Chen1, A Garg.   

Abstract

Recently, great progress has been made towards understanding the molecular basis of body fat regulation. Identification of mutations in several genes in spontaneous monogenic animal models of obesity and development of transgenic models have indicated the physiological roles of many genes in the regulation of body fat distribution. In humans, mutations in leptin, leptin receptor, prohormone convertase 1 (PC1), pro-opiomelanocortin (POMC), melanocortin 4-receptor (MC4-R), and peroxisome proliferator-activated receptor (PPAR) gamma2 genes have been described in patients with severe obesity. Most of these obesity disorders exhibit a distinct phenotype with varying degrees of hypothalamic and pituitary dysfunction and a recessive inheritance, whereas MC4-R mutation has a nonsyndromic phenotype with dominant inheritance. These mutations suggest the critical role of central signaling systems composed of leptin/leptin receptor and alpha-melanocyte stimulating hormone/MC4-R in human energy homeostasis. Although the genetic basis of monogenic disorders of body fat distribution, such as congenital generalized lipodystrophy and familial partial lipodystrophy, Dunnigan variety, is still unknown, the genes for these have recently been localized to chromosomes 9q34 and 1q21-22, respectively. The advances in our knowledge of the phenotypic manifestations and underlying molecular mechanisms of genetic body fat disorders may lead to better treatment and prevention of obesity and other disorders of adipose tissue in the future.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10508193

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  8 in total

Review 1.  Animal models of postinfectious obesity: hypothesis and review.

Authors:  M J Lyons; K Nagashima; J B Zabriskie
Journal:  J Neurovirol       Date:  2002-02       Impact factor: 2.643

2.  Frequency and significance of Pro12Ala and Pro115Gln polymorphism in gene for peroxisome proliferation-activated receptor-gamma regarding metabolic parameters in a Caucasian cohort.

Authors:  A Schäffler; N Barth; G Schmitz; B Zietz; K D Palitzsch; J Schölmerich
Journal:  Endocrine       Date:  2001-04       Impact factor: 3.633

Review 3.  Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed?

Authors:  G M Behrens; M Stoll; R E Schmidt
Journal:  Drug Saf       Date:  2000-07       Impact factor: 5.606

4.  Gene variants and binge eating as predictors of comorbidity and outcome of treatment in severe obesity.

Authors:  Natascha Potoczna; Ruth Branson; John G Kral; Grazyna Piec; Rudolf Steffen; Thomas Ricklin; Margret R Hoehe; Klaus-Ulrich Lentes; Fritz F Horber
Journal:  J Gastrointest Surg       Date:  2004-12       Impact factor: 3.452

5.  Hypothalamic, metabolic, and behavioral responses to pharmacological inhibition of CNS melanocortin signaling in rats.

Authors:  T Adage; A J Scheurink; S F de Boer; K de Vries; J P Konsman; F Kuipers; R A Adan; D G Baskin; M W Schwartz; G van Dijk
Journal:  J Neurosci       Date:  2001-05-15       Impact factor: 6.167

6.  Precision Medicine for Obesity.

Authors:  Lizeth Cifuentes; Maria Daniela Hurtado A; Jeanette Eckel-Passow; Andres Acosta
Journal:  Dig Dis Interv       Date:  2021-09

7.  Mutations in the small heterodimer partner gene are associated with mild obesity in Japanese subjects.

Authors:  H Nishigori; H Tomura; N Tonooka; M Kanamori; S Yamada; K Sho; I Inoue; N Kikuchi; K Onigata; I Kojima; T Kohama; K Yamagata; Q Yang; Y Matsuzawa; T Miki; S Seino; M Y Kim; H S Choi; Y K Lee; D D Moore; J Takeda
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

8.  Accounting for a quantitative trait locus for plasma triglyceride levels: utilization of variants in multiple genes.

Authors:  Lisa J Martin; Ahmed H Kissebah; Michael Olivier
Journal:  PLoS One       Date:  2012-04-02       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.